Leuprolide acetate 45mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal area, ...
Leuprolide acetate 7.5mg; depot susp for IM inj; preservative-free. Give as single IM inj into gluteal area, anterior thigh or deltoid; rotate inj sites. 7.5mg once a month (4 weeks). Initial ...
ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...
"Advanced prostate cancer can have a devastating impact on patients and their quality of life," says Dr. Andrew Loblaw, Clinician Scientist and Head of Genitourinary Radiation Oncology Clinical ...
Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...
ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA ...
ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cvwck3/lupron_depot) has announced the addition of GlobalData's new report ...
LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback